Study progress of blood transfusion therapy for severe β-thalassaemia major
WEI Hai-chun1 ZHENG Min2▲
Blood Transfusion Room,Maternal and Child Health Hospital of Liuzhou City,Guangxi Zhuang Autonomous Region,Liuzhou 545001,China;2.Department of Paediatric,Maternal and Child Health Hospital of Liuzhou City,Guangxi Zhuang Autonomous Region,Liuzhou 1.545001,China
Abstract:Thalassemia is a serious public health problem in the world.In China,Guangdong and Guangxi are regions of high incidence.Severe β-thalassemia is an ineffective hematopoietic or hemolytic anemia resulting from the accumulation of α -globin chain imbalance caused by the decrease or absence of β -globin production,which is a serious fatal disease.From 3 to 6 months after birth,the patient began to develop chronic progressive hemolysis,accompanied by developmental retardation,pale complexion,hepatosplenomegaly and other symptoms.As the condition worsens,bone swelling occurs.Without blood transfusion,the patientundefineds life span is as little as 5 years.Although the life span of the patients with severe β-thalassemia is significantly prolonged after regular blood transfusion,repeated blood transfusion resulted in hypothyroidism,diabetes mellitus and hyposexual function due to iron overload.Standard ironremoving therapy can lighten the iron load of patients,but long-term iron removal seriously affects the quality of life of patients,so compliance is poor.In recent years,hematopoietic stem cell transplantation (HSCT)is the only medical method to cure severe β-thalassemia.The life quality of patients with thalassemia after stem cell transplantation is significantly higher than that of patients treated with traditional blood transfusion and iron removal,but there are still problems of life-threatening complications and high cost of treatment after transplantation.
韦海春;郑敏. 重型β地中海贫血的输血治疗研究进展[J]. 中国当代医药, 2018, 25(26): 31-35.
WEI Hai-chun;ZHENG Min. Study progress of blood transfusion therapy for severe β-thalassaemia major. 中国当代医药, 2018, 25(26): 31-35.
Rahimi Z.Genetic epidemiology,hematological and clinical features of hemoglobinopathies in Iran[J].Biomed Res Int,2013,2013:803487.
[2]
Xiong F,Sun M,Zhang X,et al.Molecular epidemiological survey of haemoglobinopathies in the Guangxi Zhuang Autonomous Region of souther china[J].Clin Genet,2012,78(2):139-148.
[4]
Najjari A,Asouri M,Gouhari LH,et al.Alpha:non alpha and ggamma:agamma globin chain ratios in thalassemia intermedia patients treated with hydroxyurea[J].Asian Pac J Trop Biomed,2014,4(Suppl 1):S177-S185
[9]
Yin XL,Wu ZK,He YY,et al.Treatment and complications of thalassemia major in Guangxi,Southern China[J].Pediatr Blood Cancer,2011,57(7):1174-1178
Bas M,Gumruk F,Gonc N,et al.Biochemical markers of glucose metabolism may be used to estimate the degree and progression of iron overload in the liver and pancreas of patients with β -thalassemia major[J].Ann Hematol,2015,94(7):1099-1104.
[20]
Cappellini MD,Cohen A,Porter J,et al.Guidelines for the management of transfusion dependent thalassemia(TDT)[Z].Thalassaemia International Federation,2014.
[21]
Rashidi M,Aboomardani M,Rafraf M,et al.Effects of vitamin E and zinc supplementation on antioxidants in beta thalassemia major patients[J].Iran J Pediatr,2011,21(1):8-14.
Anderson LJ,Wonke B,Prescott R,et al.Comparison of effectsof oral deferidrone and subcutaneous desferrioxamine on mvocardial iron concentrations and ventricular function in beta-thalassaemia[J].Lancet,2002,360(9332):516-520.
[24]
Alessandrino E,Angelucci E,Cazzola M,et al.Iron overload and iron chelation therapy in patients with myelodysplastic syndrome treated by allogeneic stem-cell transplantation:report from the working conference on iron chelation of the Gruppo Italiano Trapianto di Midollo Osseo[J].Am J Hematol,2011,86(10):897-902.
[25]
Musallam KM,Angastiniotis M,Eleftheriou A,et al.Crosstalk between available guidelines for the management of patients with beta-thalassemia major[J].Acta Haematol,2013,130(2):64-73
[26]
Santra S,Bhattacharya A,Mukhopadhyay T,et al.Use of iron chelating agents in transfusion dependent thalassaemia major patients[J].Mymensingh Med J,2015,24(5):838-844.
Locatelli F,Kabbara N,Ruggeri A,et al.Outcome of patients with hemoglobinopathies given either cord blood or bone marrow transplantation from an HLA-identical sibling[J].Blood,2013,122(6):1072-1078.